comparemela.com

Latest Breaking News On - Front immunol - Page 1 : comparemela.com

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Patients with HS Shown to be at Higher Risk of Developing Osteoarthritis

In this analysis, the investigators note that the clinical association may be helpful to be taken into account as clinicians treat patients with HS.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.